Valuation: EnteroMedics Inc

Market Cap 1.51Cr 1.32Cr 1.22Cr 1.12Cr 2.12Cr 145.51Cr 2.16Cr 15Cr 5.73Cr 71Cr 5.67Cr 5.54Cr 245.3Cr P/E 2026 *
-3.05x
P/E 2027 * -2.35x
Enterprise Value 1.51Cr 1.32Cr 1.22Cr 1.12Cr 2.12Cr 145.51Cr 2.16Cr 15Cr 5.73Cr 71Cr 5.67Cr 5.54Cr 245.3Cr EV / Sales 2026 *
101x
EV / Sales 2027 * 60.4x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 2L 1L 1L 1L 2L 1.45Cr 2L 14.53L 6L 70.77L 6L 6L 2.44Cr 2L 2L 2L 2L 4L 2.41Cr 4L 24.22L 9L 1.18Cr 9L 9L 4.06Cr
Net income -48.9L -42.86L -39.62L -36.44L -68.75L -47Cr -69.85L -4.74Cr -1.86Cr -23Cr -1.84Cr -1.8Cr -79Cr -77.69L -68.1L -62.94L -57.89L -1.09Cr -75Cr -1.11Cr -7.53Cr -2.95Cr -37Cr -2.92Cr -2.85Cr -126.29Cr
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-